Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes

Abstract Background Though the incidence, characteristics, and pathogenesis of chemotherapy induced peripheral neuropathy (CIPN) by taxane based chemotherapy were extensively studied, diagnostic guidelines extent only recently. Aim To observationally investigate whether specific tests can be used to...

Full description

Bibliographic Details
Main Authors: Frank vanHaren, Sandra van denHeuvel, Mandy Ligtenberg, Kris Vissers, Monique Steegers
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Cancer Reports
Subjects:
Online Access:https://doi.org/10.1002/cnr2.1577
_version_ 1811237912175443968
author Frank vanHaren
Sandra van denHeuvel
Mandy Ligtenberg
Kris Vissers
Monique Steegers
author_facet Frank vanHaren
Sandra van denHeuvel
Mandy Ligtenberg
Kris Vissers
Monique Steegers
author_sort Frank vanHaren
collection DOAJ
description Abstract Background Though the incidence, characteristics, and pathogenesis of chemotherapy induced peripheral neuropathy (CIPN) by taxane based chemotherapy were extensively studied, diagnostic guidelines extent only recently. Aim To observationally investigate whether specific tests can be used to predict and monitor CIPN severity. Methods Fourteen female breast cancer patients receiving paclitaxel or docetaxel were evaluated using the McGill Pain Questionnaire (MPQ), National Cancer Institute Common Toxicity Criteria (NCI‐CTC) grading, clinical total neuropathy score (TNSc), quantitative sensory testing (QST) of pressure pain threshold (PPT), and numeric rating scale (NRS) scores and stocking and glove distribution testing (SGDT), at the start (T0), midst (T1), and end (T2) of their treatment and after 3 months (T3). Results At T3, patients scored NCI‐CTC neuropathy grade 1 (14.3%), 2 (64.3%), and 3 (14.3%) respectively. Fifty percentage scored at least grade 1 at T0, with complaints not caused by CIPN. Pain, if present, was denominated “tingling” and “cold” in the MPQ. Median TNSc score increased from T0 (2.43) to T1 (4.71) to T2 (5.50) to T3 (5.57), as did pinprick and cold sensation disturbances in SGDT. PPT and associated NRS remained unchanged. TNSc and SGDT at T1 could not predict the NCI‐CTC grade at T3. Conclusion NCI‐CTC, TNSc, and stocking and glove distribution testing can be used in the early diagnosis and monitoring of CIPN, with false‐positive findings at baseline. Final NCI‐CTC grades could not be predicted.
first_indexed 2024-04-12T12:31:37Z
format Article
id doaj.art-0c1be8d726a0466e835709cb11142fef
institution Directory Open Access Journal
issn 2573-8348
language English
last_indexed 2024-04-12T12:31:37Z
publishDate 2022-10-01
publisher Wiley
record_format Article
series Cancer Reports
spelling doaj.art-0c1be8d726a0466e835709cb11142fef2022-12-22T03:33:00ZengWileyCancer Reports2573-83482022-10-01510n/an/a10.1002/cnr2.1577Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanesFrank vanHaren0Sandra van denHeuvel1Mandy Ligtenberg2Kris Vissers3Monique Steegers4Department of Anesthesiology, Pain and Palliative Medicine Radboudumc Nijmegen The NetherlandsDepartment of Anesthesiology, Pain and Palliative Medicine Radboudumc Nijmegen The NetherlandsDepartment of Anesthesiology, Pain and Palliative Medicine Radboudumc Nijmegen The NetherlandsDepartment of Anesthesiology, Pain and Palliative Medicine Radboudumc Nijmegen The NetherlandsDepartment of Anesthesiology, Pain and Palliative Medicine Radboudumc Nijmegen The NetherlandsAbstract Background Though the incidence, characteristics, and pathogenesis of chemotherapy induced peripheral neuropathy (CIPN) by taxane based chemotherapy were extensively studied, diagnostic guidelines extent only recently. Aim To observationally investigate whether specific tests can be used to predict and monitor CIPN severity. Methods Fourteen female breast cancer patients receiving paclitaxel or docetaxel were evaluated using the McGill Pain Questionnaire (MPQ), National Cancer Institute Common Toxicity Criteria (NCI‐CTC) grading, clinical total neuropathy score (TNSc), quantitative sensory testing (QST) of pressure pain threshold (PPT), and numeric rating scale (NRS) scores and stocking and glove distribution testing (SGDT), at the start (T0), midst (T1), and end (T2) of their treatment and after 3 months (T3). Results At T3, patients scored NCI‐CTC neuropathy grade 1 (14.3%), 2 (64.3%), and 3 (14.3%) respectively. Fifty percentage scored at least grade 1 at T0, with complaints not caused by CIPN. Pain, if present, was denominated “tingling” and “cold” in the MPQ. Median TNSc score increased from T0 (2.43) to T1 (4.71) to T2 (5.50) to T3 (5.57), as did pinprick and cold sensation disturbances in SGDT. PPT and associated NRS remained unchanged. TNSc and SGDT at T1 could not predict the NCI‐CTC grade at T3. Conclusion NCI‐CTC, TNSc, and stocking and glove distribution testing can be used in the early diagnosis and monitoring of CIPN, with false‐positive findings at baseline. Final NCI‐CTC grades could not be predicted.https://doi.org/10.1002/cnr2.1577chemotherapyCIPNdiagnostic toolpolyneuropathytaxane
spellingShingle Frank vanHaren
Sandra van denHeuvel
Mandy Ligtenberg
Kris Vissers
Monique Steegers
Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes
Cancer Reports
chemotherapy
CIPN
diagnostic tool
polyneuropathy
taxane
title Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes
title_full Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes
title_fullStr Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes
title_full_unstemmed Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes
title_short Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes
title_sort diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes
topic chemotherapy
CIPN
diagnostic tool
polyneuropathy
taxane
url https://doi.org/10.1002/cnr2.1577
work_keys_str_mv AT frankvanharen diagnostictoolsshouldbeusedforthediagnosisofchemotherapyinducedperipheralneuropathyinbreastcancerpatientsreceivingtaxanes
AT sandravandenheuvel diagnostictoolsshouldbeusedforthediagnosisofchemotherapyinducedperipheralneuropathyinbreastcancerpatientsreceivingtaxanes
AT mandyligtenberg diagnostictoolsshouldbeusedforthediagnosisofchemotherapyinducedperipheralneuropathyinbreastcancerpatientsreceivingtaxanes
AT krisvissers diagnostictoolsshouldbeusedforthediagnosisofchemotherapyinducedperipheralneuropathyinbreastcancerpatientsreceivingtaxanes
AT moniquesteegers diagnostictoolsshouldbeusedforthediagnosisofchemotherapyinducedperipheralneuropathyinbreastcancerpatientsreceivingtaxanes